FR EN

Back


20/03/2019
Vivet Therapeutics, Idinvest's healthcare portfolio company, to collaborate with Pfizer
Pfizer has acquired a 15% equity interest in gene therapy company Vivet and secured an exclusive option to acquire the company. The two companies will collaborate with Pfizer on the development of Vivet's proprietary treatment for Wilson disease and this partnership will help them to continue to develop therapies for patients suffering from inherited liver disorders.

Download the pdf file





X

X

X